| アブストラクト | We examined case reports of immune checkpoint inhibitors (ICIs) associated pulmonary tuberculosis (PT) using data from the Food and Drug Administration Adverse Event Reporting System database. Disproportionality analysis was performed by using the reporting OR (ROR) with relevant 95% CI. A total of 74 cases of PT related to ICIs therapy were identified. ICIs were significantly associated with over-reporting frequencies of PT (ROR=3.16, 95% CI: 2.51 to 3.98), while the signal was differed between anti-programmed death-1/ligand-1 and anti-cytotoxic T lymphocyte antigen-4 agents. Most indications were lung cancer (64.9%), the median onset age was 70 years, the median time to onset of PT was 70 days, ICIs were discontinued in most cases (85.2%). |
|---|
| ジャーナル名 | Thorax |
|---|
| Pubmed追加日 | 2022/3/13 |
|---|
| 投稿者 | Zhu, Jianhong; He, Zhichao; Liang, Dan; Yu, Xiaoxia; Qiu, Kaifeng; Wu, Junyan |
|---|
| 組織名 | Department of Pharmacy, Sun-Yat-Sen Memorial Hospital, Sun Yat-sen University,;Guangzhou, People's Republic of China.;Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene;Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou,;People's Republic of China.;Guangzhou, People's Republic of China wujunyan@mail.sysu.edu.cn. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35277447/ |
|---|
